AI assistant
SOLESENCE, INC. — Director's Dealing 2018
May 24, 2018
33563_dirs_2018-05-24_43ad1e37-2535-41ba-9b6e-43c1d716d353.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NANOPHASE TECHNOLOGIES Corp (NANX)
CIK: 0000883107
Period of Report: 2018-05-23
Reporting Person: MCCLUNG JAMES A (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-05-23 | Common Stock (right to purchase) | $0.82 | A | 12000 | Acquired | 2028-05-23 | Common Stock (12000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 30071 | Indirect |
| Common Stock | 17582 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Common Stock (right to purchase) | $1.36 | 2021-01-31 | Common Stock (12000) | 12000 | Direct |
| Deferred Common Stock | $ | Common Stock (2250) | 21596 | Direct | |
| Common Stock (right to purchase) | $0.30 | 2022-08-07 | Common Stock (12000) | 12000 | Direct |
| Common Stock (right to purchase) | $0.415 | 2023-02-14 | Common Stock (12000) | 12000 | Direct |
| Common Stock (right to purchase) | $0.52 | 2024-02-13 | Common Stock (12000) | 12000 | Direct |
| Common Stock (right to purchase) | $0.44 | 2025-02-18 | Common Stock (10800) | 10800 | Direct |
| Common Stock (right to purchase) | $0.42 | 2026-02-23 | Common Stock (9720) | 9720 | Direct |
| Common Stock (right to purchase) | $0.90 | 2026-11-17 | Common Stock (2250) | 2250 | Direct |
| Common Stock (right to purchase) | $1.05 | 2026-11-17 | Common Stock (2250) | 2250 | Direct |
| Common Stock (right to purchase) | $1.18 | 2026-11-17 | Common Stock (2250) | 2250 | Direct |
| Common Stock (right to purchase) | $0.84 | 2026-11-17 | Common Stock (2250) | 2250 | Direct |
| Common Stock (right to purchase) | $1.85 | 2026-11-17 | Common Stock (2250) | 2250 | Direct |
| Common Stock (right to purchase) | $1.10 | 2026-11-17 | Common Stock (2250) | 2250 | Direct |
| Common Stock (right to purchase) | $0.99 | 2026-11-17 | Common Stock (2250) | 2250 | Direct |
| Common Stock (right to purchase) | $0.68 | 2027-02-21 | Common Stock (12000) | 12000 | Direct |
Footnotes
F1: Subject to certain rights and restrictions, beginning on this date, options vest in three equal annual installments.
F2: Each share of deferred common stock represents a right to receive one share of common stock.
F3: The deferred common stock becomes payable upon the reporting person's termination of service as a director of the Company.
F4: Pursuant to such plan, the reporting person elected to defer receipt of such shares and receive a cumulative total of 21,596 shares of deferred common stock which will all be accounted for under the Company's Non-Employee Director Deferred Compensation Plan.
F5: Beginning on this date, and subject to certain restrictions, the stock options vest in three equal annual installments.
F6: Beginning on this date, and subject to certain restrictions, options vest in three equal annual installments.
F7: The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99.